EU
Emory University Portfolio holdings
AUM
$27.7M
This Quarter Return
+4.86%
1 Year Return
+31.53%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$52.9M
AUM Growth
+$52.9M
(+15%)
Cap. Flow
+$6.01M
Cap. Flow
% of AUM
11.36%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
10
New
9
Increased
–
Reduced
1
Closed
–
Top Buys
| 1 |
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
|
$1.35M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$1.21M |
| 3 |
Incyte
INCY
|
$1.17M |
| 4 |
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
|
$1.05M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$1.04M |
Top Sells
| 1 |
Vanguard FTSE Emerging Markets ETF
VWO
|
$3.6M |
Sector Composition
| 1 | Healthcare | 11.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Vanguard FTSE Emerging Markets ETF
VWO
$96.4B
| $43.3M | 81.83% | 1,058,781 -88,119 | -8% | -$3.6M |
|
|
ANAC
2
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $1.35M | 2.55% | +23,325 | New | +$1.35M |
|
|
3
BioMarin Pharmaceuticals
BMRN
$11.2B
| $1.21M | 2.29% | +9,715 | New | +$1.21M |
|
|
4
Incyte
INCY
$16.5B
| $1.17M | 2.21% | +12,729 | New | +$1.17M |
|
|
BLCM
5
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $1.05M | 1.98% | +45,261 | New | +$1.05M |
|
|
SGEN
6
DELISTED
Seagen Inc. Common Stock
SGEN
| $1.04M | 1.97% | +29,535 | New | +$1.04M |
|
|
GHDX
7
DELISTED
Genomic Health, Inc.
GHDX
| $983K | 1.86% | +32,167 | New | +$983K |
|
|
GEVA
8
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
| $961K | 1.82% | +9,854 | New | +$961K |
|
9
Acadia Pharmaceuticals
ACAD
$4.38B
| $957K | 1.81% | +29,356 | New | +$957K |
|
10
BioCryst Pharmaceuticals
BCRX
$1.74B
| $886K | 1.68% | +98,161 | New | +$886K |
|